EyePoint Pharmaceuticals, Inc. - EYPT STOCK NEWS

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a nine-month extension of DEXYCU®'s pass-through payment status following a draft ruling by the Centers for Medicare and Medicaid Services (CMS). This extension, set to last until December 31, 2022, aids in the coverage of outpatient drugs during cataract surgeries, impacting approximately 60% of Medicare Part B patients. The final ruling from CMS is expected in November 2021. CEO Nancy Lurker expressed optimism about the extension, emphasizing its significance for DEXYCU's commercial strategy.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has reported positive safety results from its Phase 1 clinical trial of EYP-1901, aimed at treating wet age-related macular degeneration (wet AMD). The trial involved 17 patients and showed no serious adverse events after 30-day follow-ups. The company anticipates releasing interim efficacy results in Q4 2021 and plans to initiate trials for diabetic retinopathy and retinal vein occlusion. EYP-1901 utilizes proprietary Durasert® technology for sustained drug delivery, demonstrating the company's commitment to advancing eye disorder treatments.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that the American Medical Association accepted a new Category III CPT code (0X78T) for drug administration in the eye, effective January 1, 2022. This code provides a reimbursement pathway for DEXYCU, the first FDA-approved sustained-release intracameral steroid for postoperative inflammation treatment. The approval is seen as a significant step toward increased adoption of DEXYCU, enhancing its market presence and financial prospects.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced its inclusion in the small-cap Russell 2000® Index and the broader Russell 3000® Index, effective June 28, 2021. This addition reflects the company’s position among approximately 2,000 smaller companies based on market capitalization.

The Russell indexes are critical benchmarks for investment strategies, managing $10.6 trillion in assets. EyePoint focuses on therapeutics for serious eye disorders, leveraging its proprietary Durasert® technology and two commercial products, YUTIQ® and DEXYCU®.

EyePoint Pharmaceuticals (NASDAQ: EYPT) will have CEO Nancy Lurker speak at the Jefferies Healthcare Conference on June 2, 2021, at 9:30 a.m. ET. The session will explore the company's commitment to developing therapies for serious eye disorders, including innovations like EYP-1901, a treatment for wet age-related macular degeneration. Attendees can access a live webcast and a 90-day archive via EyePoint's website. The company also markets YUTIQ and DEXYCU for eye disorder treatments.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced successful enrollment completion for its Phase 1 trial of EYP-1901, a potential twice-yearly treatment for wet age-related macular degeneration (wet AMD). The trial includes dose escalation for patients previously responsive to anti-VEGF therapies. Interim data is expected in Q4 2021. EYP-1901 employs EyePoint’s Durasert technology for sustained delivery, potentially improving treatment outcomes for patients. The company aims to explore additional applications for EYP-1901, including diabetic retinopathy.

EyePoint Pharmaceuticals (EYPT) reported a productive first quarter of 2021, achieving net product revenues of $6.8 million, a 45% increase from $4.7 million in Q1 2020. The company completed a $115.1 million follow-on financing, enhancing its development pipeline. The Phase 1 DAVIO study for EYP-1901 targeting wet AMD is on track for initial data in Q4 2021. However, total net revenue declined slightly to $7.3 million from $7.5 million year-over-year. The net loss was $12.3 million, or ($0.50) per share, an improvement from a loss of $13.2 million in the same quarter last year.

EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to host a conference call on May 5, 2021, at 8:30 a.m. ET to announce its Q1 2021 financial results and discuss corporate developments. The call will be accessible via phone and a live webcast on the company’s website. EyePoint focuses on therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery. Its commercial products include YUTIQ® for chronic uveitis and DEXYCU® for postoperative inflammation.

EyePoint Pharmaceuticals (EYPT) reported financial results for Q4 and the full year ended December 31, 2020. Total net revenue increased to $34.4 million, up from $20.4 million in 2019. Net product revenue for the year was $20.8 million, compared to $16.8 million in the prior year. However, the company incurred a net loss of $45.4 million, or $3.54 per share. EyePoint raised $115.1 million through a public stock offering in February 2021, strengthening their financial position. They also highlighted progress in their EYP-1901 clinical trial for wet AMD.